Early Lapatinib-Induced Skin Rash Predicts Better Survival With

Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.

Frontiers Mechanism of Lethal Skin Toxicities Induced by

First-line lapatinib trials in metastatic breast cancer

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal

Clinical management of cutaneous adverse events in patients on

Interdisciplinary management of EGFR-inhibitor-induced skin

Anticancer pan-ErbB inhibitors reduce inflammation and tissue

Frontiers Predicting Lapatinib Dose Regimen Using Machine

PDF) Lapatinib and lapatinib plus trastuzumab therapy versus

Beyond trastuzumab: novel therapeutic strategies in HER2-positive

Interdisciplinary management of EGFR-inhibitor-induced skin

Lapatinib with trastuzumab for HER2-positive early breast cancer

Cancers, Free Full-Text

Efficacy of lapatinib monotherapy on occult breast cancer

Clinical management of cutaneous adverse events in patients on

Frontiers Mechanism of Lethal Skin Toxicities Induced by